Preliminary evaluation of a bunyavirus vector for cancer immunotherapy

N. Oreshkova; L. Spel; R. P M Vloet; P. J. Wichgers Schreur; R. J M Moormann; M. Boes; J. Kortekaas

doi:10.1128/JVI.01105-15

Preliminary evaluation of a bunyavirus vector for cancer immunotherapy

N. Oreshkova, L. Spel, R. P M Vloet, P. J. Wichgers Schreur, R. J M Moormann, M. Boes, J. Kortekaas^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8<sup>+</sup> T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.

Original language	English
Pages (from-to)	9124-9127
Number of pages	4
Journal	Journal of Virology
Volume	89
Issue number	17
DOIs	https://doi.org/10.1128/JVI.01105-15
Publication status	Published - 1 Jan 2015

Access to Document

10.1128/JVI.01105-15

9124.fullFinal published version, 1.26 MB

Cite this

@article{a35920dcd2b84be5894a7dd20cc1b2d6,

title = "Preliminary evaluation of a bunyavirus vector for cancer immunotherapy",

abstract = "Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+ T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.",

author = "N. Oreshkova and L. Spel and Vloet, {R. P M} and {Wichgers Schreur}, {P. J.} and Moormann, {R. J M} and M. Boes and J. Kortekaas",

year = "2015",

month = jan,

day = "1",

doi = "10.1128/JVI.01105-15",

language = "English",

volume = "89",

pages = "9124--9127",

journal = "Journal of Virology",

issn = "0022-538X",

publisher = "American Society for Microbiology",

number = "17",

}

TY - JOUR

T1 - Preliminary evaluation of a bunyavirus vector for cancer immunotherapy

AU - Oreshkova, N.

AU - Spel, L.

AU - Vloet, R. P M

AU - Wichgers Schreur, P. J.

AU - Moormann, R. J M

AU - Boes, M.

AU - Kortekaas, J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+ T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.

AB - Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8+ T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84938906815&partnerID=8YFLogxK

U2 - 10.1128/JVI.01105-15

DO - 10.1128/JVI.01105-15

M3 - Article

AN - SCOPUS:84938906815

SN - 0022-538X

VL - 89

SP - 9124

EP - 9127

JO - Journal of Virology

JF - Journal of Virology

IS - 17

ER -

Preliminary evaluation of a bunyavirus vector for cancer immunotherapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this